吴功伟 特聘教授、特聘研究员
邮箱：wugongwei@ucas.ac.cn
研究领域：肿瘤生物学、淋巴瘤、表观遗传学、临床转化
招生专业：细胞生物学、生物化学与分子生物学、生物技术与工程
博士生导师，从事恶性肿瘤演进及治疗新策略的研究，以第一或通讯作者（含共同）在Science Translational Medicine, Nature Communications, Advanced Science, EMBO Reports等国际学术期刊发表SCI论文18篇，开展临床1/2期试验1项。以PI身份主持美国国立癌症研究院和美国白血病与淋巴瘤协会等4项国际基金约180万美元，受邀在AACR和ASH国际大会作口头报告，获LLS Fellow Award、AACR Lymphoma Research Fellowship (Declined)、HHMI Scholarship、ASH Abstract Achievement Award、中国科学院院长特别奖等奖项，受邀担任 Advanced Materials、Journal Hematology & Oncology、Advanced Science、Leukemia、eLife等期刊的审稿人。
课题组致力于“肿瘤演进及治疗新策略”的研究，采取多种手段，整合前沿组学方法、患者临床样本、病人源异种移植瘤模型、转基因小鼠模型、细胞系和CRISPR/Cas9基因编辑等技术和策略，深入研究恶性肿瘤的致病机理、新技术及治疗新策略。课题组的目标是将基础研究转化为临床前和临床应用，并最终造福我们的肿瘤患者，提升他们的生命质量。
课题组长期招收博后和研究生，方向包括湿实验和干实验，并欢迎本科生提前进入实验室进行培养。欢迎对课题组研究方向感兴趣的同学发送邮件联系。
教育背景及科研经历
2007.09-2011.06 华中科技大学，本科生
2010.06-2010.08 中国科学院生物化学与细胞生物学研究所，研究实习生
2011.09-2017.06 中国科学技术大学，博士研究生
2017.06-2017.12 中国科学技术大学，助理研究员
2017.11-2023.10 哈佛大学医学院、丹娜-法伯癌症研究所，博士后
2023.11-2025.01 哈佛大学医学院、丹娜-法伯癌症研究所，讲师
发表论文
Google Scholar: https://scholar.google.com/citations?user=G4dASwUAAAAJ&hl=en
*Co-first authors #co-corresponding authors
1、Wu G#, Yoshida N, Liu J, Zhang X, Xiong Y, Heavican-Foral TB, Mandato E, Liu H, Nelson GM, Yang L, Chen R, Donovan KA, Jones MK, Roshal M, Zhang Y, Xu R, Nirmal AJ, Jain S, Leahy C, Jones KL, Stevenson KE, Galasso N, Ganesan N, Chang T, Wu WC, Louissaint A, Debaize L, Yoon H, Dal Cin P, Chan WC, Ho Sui SJ, Ng SY, Feldman AL, Horwitz SM, Adelman K, Fischer ES, Chen CW, Weinstock DM#, Brown M#. TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence. Science Translational Medicine. 2023 Sep 20;15(714): eadi7244.
2、Liu H*, Chen W*, Wu G*, Zhou J, Liu C, Tang Z, Huang X, Gao J, Xiao Y, Kong N, Joshi N, Cao Y, Abdi R, Tao W. Glutathione‐Scavenging Nanoparticle‐Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects. Advanced Science. 2023, 2207439.
3、Wu G#*, Suo C*, Yang Y, Shen S, Sun L, Li S, Zhou Y, Yang D, Wang Y, Cai Y, Wang N, Zhang H, Yang Y-G#, Cao J#, Gao P#. MYC promotes cancer progression by modulating m6A modifications to suppress target gene translation. EMBO reports. 2021 Jan 11; e51519.
4、Wu G, Yuan M, Shen S, Ma X, Fang J, Zhu L, Sun L, Liu Z, He X, Huang, Li T, Li C, Wu J, Hu X, Li Z, Song L, Qu K, Zhang H, Gao P. Menin enhances c-Myc-mediated transcription to promote cancer progression. Nat Commun. 2017 May 5;8:15278.
5、Liu J*, Xing L*, Li J, Wen K, Liu N, Liu Yu, Wu G, Wang S, Ogiya D, Song TY, Kurata K, Penailillo J, Morelli E, Wang T, Hong X, Gulla A, Tai YT, Munshi N, Richardson P, Carrasco R, Hideshima T, Anderson KC#. Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma. Nat Commun. 2024 Feb 14;15:1367.
6、Jiang B, Weinstock D, Donovan K, Sun H, Wolfe A, Amaka S, Donaldson N, Wu G, Jiang Y, Wilcox R, Fisher E, Gray N, Wu W. ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas. Cell Chemical Biology. 2023, S2451-9456.
7、Kong N, Zhang R, Wu G, Sui X, Wang J, Kim NY, Blake S, De D, Xie T, Cao Y, Tao W. Intravesical Delivery of KDM6A-1 mRNA via Mucoadhesive Nanoparticles Inhibits the Metastasis of Bladder Cancer. Proc Natl Acad Sci U S A. 2022, 119, 7, e2112696119.
8、Wu W, Nelson GM, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, Nirmal AJ, Liu H, Yang L, Duffy J, Powers F, Stevenson KE, Jones MK, Ng SY, Wu G, Jain S, Xu R, Amaka S, Trevisani C, Donaldson NL, Hagner PR, de Leval L, Gaulard P, Iqbal J, Thakurta A, Fischer ES, Adelman K, Weinstock DM. Overcoming IMiD Resistance in T-cell Lymphomas Through Potent Degradation of ZFP91 and IKZF1. Blood. 2021.
9、Huang X, Wu G, Liu C, Liu C, Hua X, Tang Z, Xiao Y, Chen W, Zhou J, Kong N, Huang P, Shi J, Tao W. Intercalation-Driven Formation of siRNA Nanogels for Cancer Therapy. Nano Letters. 2021, 21, 22, 9706–9714.
10、Liu C, Sun S, Feng Q, Wu G, Wu Y, Kong N, Yu Z, Yao J, Zhang X, Chen W, Tang Z, Xiao Y, Huang X, Lv A, Yao C, Cheng H, Wu A, Xie T, Tao W. Arsenene Nanodots with Selective Killing Effects and their Low-Dose Combination with ß-Elemene for Cancer Therapy. Advanced Materials. 2021, 33(37): 2102054.
11、Zee BM, Poels KE, Yao CH, Kawabata KC, Wu G, Duy C, Jacobus WD, Senior E, Endress JE, Jambhekar A, Lovitch SB, Ma J, Dhall A, Harris IS, Blanco MA, Sykes DB, Licht JD, Weinstock DM, Melnick A, Haigis MC, Michor F, Shi Y. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. iScience. 2021 May 25;24(6):102651.
12、Liu Z, Sun L, Cai Y, Shen S, Zhang T, Wang N, Wu G, Ma W, Li S, Suo C, Hao Y, Jia W, Semenza G, Gao P, Zhang H. Hypoxia-induced suppression of alternative splicing of MBD2 promotes breast cancer metastasis via activation of FZD1. Cancer Res. 2021 Jan 5;canres.2876.2020.
13、Li S, Huang D, Shen S, Cai Y, Xing S, Wu G, Jiang Z, Hao Y, Yuan M, Wang N, Zhu L, Yan R, Yang D, Wang L, Liu Z, Hu X, Zhou R, Qu K, Li A, Duan X, Zhang H1, Gao P. Myc-mediated SDHA Acetylation Triggers Epigenetic Regulation of Gene Expression and Tumorigenesis. Nature Metabolism. 2020 March 16; 2:256-269.
14、Zhong X, Tian S, Zhang X, Diao X, Dong F, Yang J, Li Z, Sun L, Wang L, He X, Wu G, Hu X, Wang L, Song L, Zhang H, Pan X, Li A, Gao P. CUE domain-containing protein 2 promotes the Warburg effect and tumorigenesis. EMBO Rep. 2017 May;18(5):809-825.
15、Huang, Li T, Wang L, Zhang L, Yan R, Li K, Xing S, Wu G, Hu L, Jia W, Lin SC, Dang CV, Song L, Gao P, Zhang H. Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress. Cell Res. 2016 Oct;26(10):1112-1130.
16、Sun L, Song L, Wan Q, Wu G, Li X, Wang Y, Wang J, Liu Z, Zhong X, He X, Shen S, Pan X, Li A, Wang Y, Gao P, Tang H, Zhang H. cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res. 2015 Apr;25(4):429-44.
17、Ma X, Li C, Sun L, Huang D, Li T, He X, Wu G, Yang Z, Zhong X, Song L, Gao P, Zhang H. Lin28/let-7 axis regulates aerobic glycolysis and cancer progression via PDK1. Nat Commun. 2014 Oct 10;5:5212.
18、Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, Fang Z, Wu J, Han X, Zhang J, Sun Y, Wu G, Padera R, Chen H, Wong KK, Ge G, Ji H. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18892-7.
